Lotte Chilsung Beverage (005300) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
Consolidated sales for Q2 2026 rose 2.4% year-over-year to 11,129 billion KRW, with 1H 2026 sales up 3.4% to 20,654 billion KRW.
Operating profit for Q2 2026 declined 10.4% year-over-year to 558 billion KRW, but 1H 2026 operating profit increased 18.6% to 1,036 billion KRW.
Net profit for Q2 2026 was 282 billion KRW, up 1.7% year-over-year; 1H 2026 net profit surged 61.4% to 535 billion KRW.
Beverage segment contributed 80% of revenue and 71.7% of operating profit; liquor segment accounted for 20% of revenue.
Maintained robust financial position with total assets of KRW 4,371.3 billion and equity of KRW 1,638.9 billion.
Financial highlights
Gross profit for Q2 2026 was 3,772 billion KRW, up 2.4% year-over-year, with a gross margin of 33.9%.
Q2 2026 operating margin was 5.0%, down from 5.7% in Q2 2025.
Debt to equity ratio as of June 30, 2026, was 166.7%.
Basic EPS for ordinary shares was KRW 4,972 for H1 2026, compared to KRW 3,166 in H1 2025.
Gross margin improved to 34.6% from 33.2% year-over-year.
Outlook and guidance
Full-year 2026 consolidated sales are guided at 41,000 billion KRW, up 3.2% year-over-year.
Operating profit is projected to reach 2,000 billion KRW, a 19.6% increase year-over-year.
Targeting a shareholder return rate of 30% on a consolidated basis, with continued focus on dividend stability and capital return.
Plans to expand zero-calorie and health-oriented product lines and strengthen overseas market presence.
Action plans include minimizing raw material cost impact and expanding the sales network to mitigate fixed cost burden.
Latest events from Lotte Chilsung Beverage
- Q1 2026 delivered sharp profit gains, margin expansion, and robust overseas segment growth.005300
Q1 2026 - Domestic sales and profits fell in Q4 2025, but overseas growth and 2026 recovery are forecast.005300
Q4 2025 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 2025 - Profit growth in Q2 2025 driven by overseas and zero-calorie products, with strong full-year outlook.005300
Q2 2025 - Sales and profits fell, but zero-calorie and health products drove segment growth.005300
Q3 2024 - Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 2024 - Q1 2025 revenue and profit declined, with rising debt ratio and segment performance shifts.005300
Q1 2025 - Record sales in 2024 offset by profit decline; 2025 targets strong growth and margin recovery.005300
Q4 2024